相关实验视频

Updated: Jun 5, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

化学抗原受体-T细胞治疗后的第二种原发性癌症:一篇评论

Shyam A Patel¹, Jay Y Spiegel², Saurabh Dahiya³

¹Division of Hematology and Oncology, Department of Medicine, Center for Clinical and Translational Science, UMass Chan Medical School, Worcester.

|December 12, 2024

概括

化学抗原受体-T细胞 (CAR-T) 疗法对血液癌症有希望,但存在第二原发性癌症 (SPC) 的风险. 目前的证据表明,与CAR-T转基因插入的相关性有限,但缓解策略至关重要.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
遗传学是一个遗传学.

背景情况:

化学抗原受体-T细胞 (CAR-T) 疗法已经彻底改变了血液癌症治疗.
人们对在CAR-T治疗后出现第二次原发性癌症 (SPC) 的风险表示担忧.
报告的SPC主要是转基因阴性,罕见的转基因阳性病例.

研究的目的:

在CAR-T治疗后审查SPC的流行病学和病理生物学.
讨论潜在的策略,以减轻SPC风险在CAR-T接受者.
评估CAR-T转基因插入与SPC开发之间的关联.

主要方法:

在CAR-T治疗后报告的SPC病例的文献综述.
流行病学数据和病理生物学机制的分析.
讨论风险减轻策略. 讨论风险减轻策略.

主要成果:

目前有限的数据将无意的转基因插入与CAR-T环境中的SPC联系起来.
大多数报告的SPC与CAR-T转基因无关.
证据支持持续监测和降低风险的必要性.

结论:

虽然CAR-T疗法是有效的,但需要对SPC保持警.
风险减轻策略包括优化T细胞制造和基因组测试.
下一代CAR-T产品应优先考虑最小的SPC风险,以保持有利的利益风险概况.

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...